Dr Fabian Falkenbach speaks to ecancer about a multicentric, prospective, randomised controlled trial comparing best systemic therapy (BST) with radical prostatectomy or BST alone in the management of men with pauci-metastatic prostate cancer.

Prostate cancer treatment focuses on patients with limited metastatic disease, highlighting the benefits of local treatments like radiotherapy and radical prostatectomy.

The RAMPP trial evaluates treatment efficacy for oligometastatic cancer but is pre-closed due to ethical concerns after notable survival improvements.

Significant results in cancer-specific mortality are observed after five years, showing that both surgery and radiotherapy enhance survival, though advanced-stage patients face higher complication risks.